Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry

Japanese major Daiichi-Sankyo is preparing to cut up to 1,200 mainly sales positions in the US ahead of the loss of exclusivity for blockbuster antihypertensive Benicar, and amid a shift in its business model away from primary care and toward specialty products.